German pharma Bill "won't cut drug costs" as IQWiG ups staffing by a third
This article was originally published in Scrip
Dr Andreas Gerber, head of the department for health economics at Germany's health technology assessment body, the Institute for Quality and Efficiency in Health Care (IQWiG), has questioned the role of the AMNOG Bill, which is re-organising the pharmaceutical sector and is expected to be passed today (11 November), saying it will not slow down growth in drug costs.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.